| Literature DB >> 30513251 |
Mark McMillan1,2, Luke Walters3, Turra Mark3, Andrew Lawrence3, Lex E X Leong4, Thomas Sullivan5, Geraint B Rogers4, Ross M Andrews6,7, Helen S Marshall1,2.
Abstract
OBJECTIVES: N. meningitidis carriage in Australia is poorly understood. This study aimed to estimate prevalence and risk factors for carriage of N. meningitidis in South Australian university students. We also sought to identify whether delayed freezing of oropharyngeal samples altered PCR positivity, cycle threshold, or culture positivity.Entities:
Keywords: adolescents; carriage; risk factors; saliva
Mesh:
Year: 2019 PMID: 30513251 PMCID: PMC6605849 DOI: 10.1080/21645515.2018.1551672
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452
Characteristics of students at visit 1.
| Participant characteristics | |
|---|---|
| 18.5 (1.4) | |
| Male | 183 (43.6%) |
| Female | 237 (56.4%) |
| 6 (1.4%) | |
| 54 (12.8%) | |
| Not taken in the past month | 382 (90.7%) |
| Stopped in the last week | 8 (1.9%) |
| Stopped in the last month | 15 (3.6%) |
| YES, currently taking | 16 (3.8%) |
| 8 (1.9%) | |
| 1 (0.2%) | |
| 14 (3.3%) | |
| Yes outside | 56 (13.7%) |
| Yes inside | 4 (1.0%) |
| 0 | 207 (50.5%) |
| 1 | 118 (28.9%) |
| >2 | 85 (20.7%) |
| 0 | 272 (66.8%) |
| 1 | 126 (31.0%) |
| >2 | 9 (2.2%) |
| 115 (28.2%) | |
| 5 (4.5%) | |
| <5 people | 289 (70.7%) |
| 5 to <10 people | 104 (25.4%) |
| ≥10 people | 16 (3.9%) |
| Aboriginal | 4 (1.0%) |
| Caucasian | 269 (65.1%) |
| Asian | 111 (26.9%) |
| Middle East | 6 (1.5%) |
| African | 1 (0.2%) |
| Pacific Islander | 1 (0.2%) |
| Other | 21 (5.1%) |
Figure 1.Flow-chart of inclusion and follow-up.
Proportion of Neisseria meningitidis pharyngeal carriage from oropharyngeal swab, at visit 1 (participants who were lost to follow up), visit 1 (returned for follow up swab), and combined total.
| Visit 1 swab in those lost to follow up (n = 162) | Visit 1 swab in those who returned for visit 2 (n = 259) | Visit 1 swab in all participants (n = 421) | ||||
|---|---|---|---|---|---|---|
| Serogroup | N (%) | 95% CI | N (%) | 95% CI | N (%) | 95% CI |
| 4 (2.5%) | 0.9% to 6.5% | 3 (1.2%) | 0.4% to 3.6% | 7 (1.7%) | 0.8% to 3.5% | |
| 2 (1.2%) | 0.3 to 4.9% | 1 (0.4%) | 0.05% to 2.7% | 3 (0.7%) | 0.2% to 2.2% | |
| 6 (3.7%) | 1.7% to 8.1% | 6 (2.3%) | 1.0% to 5.1% | 12 (2.9%) | 1.6% to 5.0% | |
| 5 (3.1%) | 1.3% to 7.3% | 1 (0.4%) | 0.05% to 2.7% | 6 (1.4%) | 0.6% to 3.1% | |
| 16* (9.9%) | 6.1% to 15.6% | 10* (3.9%) | 2.1% to 7.1% | 26*(6.2%) | 4.2% to 8.9% | |
* Less than the individual serogroup total because more than one isolate has been detected in two participants (B, Y and W, Y)
Proportion of Neisseria meningitidis carriage at visit 2, in oropharyngeal swab, and saliva sample.
| Visit 2 swab (n = 259) | Visit 2 saliva sample (n = 239) | |||
|---|---|---|---|---|
| Genogroup | N (%) | 95% CI | N (%) | 95% CI |
| 3 (1.2%) | 0.4% to 3.6% | 3 (1.3%) | 0.4% to 3.8% | |
| 1 (0.4%) | 0.1% to 2.7% | 0 (0%) | ||
| 7 (2.7%) | 1.3% to 5.6% | 4 (1.7%) | 0.6% to 4.4% | |
| 5 (1.9%) | 0.8% to 4.6% | 6 (2.5%) | 1.1% to 5.5% | |
| 16 (6.2%) | 3.8% to 9.9% | 13 (5.4%) | 3.2% to 9.2% | |
Univariable logistic regression of PCR positive adolescents at visit 1, with participant characteristics.
| Effect | Detected N (%) | Odds Ratio (95% CI) | P‐value | |
|---|---|---|---|---|
| 5/66 (7.6%) | ||||
| 18 years | 11/223 (4.9%) | 0.63 (0.21 to 1.89) | 0.41 | |
| 19 years | 7/67 (10.5%) | 1.42 (0.43 to 4.73) | 0.57 | |
| >20 years | 3/65 (4.6%) | 0.59 (0.14 to 2.58) | 0.48 | |
| 14/183 (7.7%) | ||||
| Female | 12/237 (5.1%) | 0.64 (0.29 to 1.42) | 0.28 | |
| 20/367 (5.5%) | ||||
| Current cold or sore throat | 6/54 (11.1%) | 2.17 (0.83 to 5.67) | 0.11 | |
| 24/382 (6.3%) | ||||
| Use in the last month | 2/39 (5.1%) | 0.80 (0.18 to 3.55) | 0.78 | |
| 25/413 (6.1%) | ||||
| Smoker | 1/8 (12.5%) | 2.22 (0.26 to 18.73) | 0.47 | |
| 26/420 (6.2%) | ||||
| E-cig user | 0/1 (0%) | 1 | ||
| 24/407 (5.9%) | ||||
| Use in the last month | 2/14 (14.3%) | 2.66 (0.56 to 12.57) | 0.22 | |
| 24/348 (6.9%) | ||||
| Smoking residence | 2/60 (3.3%) | 0.47 (0.11 to 2.02) | 0.31 | |
| 5/207 (2.4%) | ||||
| One visit in the last week | 8/118 (6.8%) | 2.94 (0.94 to 9.20) | 0.06 | |
| Two or more in the last week | 13/85 (15.3%) | 7.29 (2.51 to 21.18) | <0.001 | |
| 7/272 (2.6%) | ||||
| One or more person | 17/135 (12.6%) | 5.45 (2.20 to 13.50) | <0.001 | |
| 15/293 (5.1%) | ||||
| Current partner | 11/115 (9.6%) | 1.96 (0.87 to 4.41) | 0.10 | |
| 18/289 (6.2%) | ||||
| > than 5 people | 8/120 (6.7%) | 1.08 (0.45 to 2.54) | 0.85 | |
| 26/413 (6.3%) | ||||
| Confirmed vaccination | 0/6 (0%) | 1 | ||
| 20/269 (7.4%) | ||||
| Asian | 3/111 (2.7%) | 0.36 (0.10 to 1.88) | 0.09 | |
| Other | 3/33 (9.1%) | 1.25 (0.35 to 4.44) | 0.74 |
Genotypic characterization of recovered isolates from throat and saliva samples by meningotype and PubMLST finetyping analysis among participants.
| Clonal complex (CC) | Number of isolates, per swab, saliva and visit | MLST (% of isolate) | Serogroup(s) (% of isolates) | PorA type (% of isolates) | FetA | fHbp | BAST |
|---|---|---|---|---|---|---|---|
| 11 | Swab 1: 2 | ST-11 (33) | W (100) | P1.5,2 (100) | F1-1 (100) | 22 (100) | 2 (100) |
| Swab 2: 1 | ST-1287 (67) | ||||||
| | Saliva: 0 | | | | | | |
| 23 | Swab 1: 7 | ST-23 (62) | Y (100) | P1.5–1,10–1 (38) | F4-1 (92) | 25 (100) | 221 (38) |
| Swab 2: 4 | ST-1655 (38) | P1.5,2 (23) | F5–12 (8) | 427 (23) | |||
| Saliva: 2 | P1.5–2,10–1 (31) | 228 (31) | |||||
| | | | | P1.5–2,10–29 (8) | | | 1212 (8) |
| 32 | Swab 1: 1 | ST-32 (100) | B (100) | P1.7,16–26 (100) | F3-3 (100) | 224 (100) | U (100) |
| Swab 2: 0 | |||||||
| | Saliva: 0 | | | | | | |
| 35 | Swab 1: 2 | ST-35 (100) | NG (100) | P1.22–1,14 (50) | F3-9 (100) | 16 (100) | U (100) |
| Swab 2: 1 | P1.18–1 (50) | ||||||
| | Saliva: 1 | | | | | | |
| 41/44 | Swab 1: 3 | ST-44 (50) | B (83) | P1.18,25–19 (33) | F1-5 (83) | 19 (100) | 315 (33) |
| Swab 2: 2 | ST-1097 (17) | NG (17) | P1.18–1,34 (33) | F1-7 (17) | U (67) | ||
| Saliva: 1 | ST-6058 (17) | P1.17–1,1 (17) | |||||
| | | ST-13,605 (17) | | P1.19–1,26–4 (17) | | | |
| 53 | Swab 1: 0 | ST-53 (100) | cnl (100) | P1.7,30–4 (100) | F1-2 (100) | 102 (100) | 1746 (100) |
| Swab 2: 1 | |||||||
| | Saliva: 1 | | | | | | |
| 167 | Swab 1: 3 | ST-167 (25) | Y (100) | P1.5–1,10–1 (25) | F5-2 (25) | 714 (25) | U (25) |
| Swab 2: 1 | ST-1624 (75) | P1.5-1,10–4 (75) | F3-4 (75) | 24 (75) | 261 (75) | ||
| | Saliva: 0 | | | | | | |
| 198 | Swab 1: 3 | ST-823 | cnl (100) | P1.17,9 (33) | F5-5 | 4 (67) | U (67) |
| Swab 2: 0 | (100) | P1.18,25 (33) | (100) | 31 (33) | 1485 (33) | ||
| | Saliva: 0 | | | P1.18,ND (33) | | | |
| 213 | Swab 1: 1 | ST-213 (100) | B (100) | P1.22,14 (100) | F5-36 (100) | 45 (100) | U (100) |
| Swab 2: 0 | |||||||
| | Saliva: 0 | | | | | | |
| 1157 | Swab 1: 0 | ST-1157 (100) | E (100) | P1.21–7,16 (100) | F5-36 (100) | 13 (100) | U (100) |
| Swab 2: 1 | |||||||
| | Saliva: 0 | | | | | | |
| 4821 | Swab 1: 1 | ST-3469 (100) | B (100) | P1.17–6,23– 7 (100) | F3-36 (100) | 16 (100) | U (100) |
| Swab 2: 1 | |||||||
| | Saliva: 1 | | | | | | |
| U | Swab 1: 3 | ST-13,603 (50) | B (50) | P1.22,14–6 (50) | F1-4 (50) | 101 (50) | 1921 (50) |
| Swab 2: 2 | ST-13,602 (17) | cnl (33) | P1.19,15 (17) | F3-28 (17) | 25 (17) | 427 (17) | |
| Saliva: 1 | ST-13,604 (17) | Y (17) | P1.5,2 (17) | F4-1 (17) | U (33) | U (33) | |
| ST-13,606 (17) | P1.ND,ND (17) | F2-5 (17) |
*NG – non-groupable; U – unknown